Results 241 to 250 of about 69,683,828 (280)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8⁺ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. [PDF]

J Gastroenterol Hepatol
Wu F, Guo Z, Guan J, Xu J, Chen Y, Chen Z.   +5 more
europepmc   +1 more source

Intedeukin 15, IL-15

The Journal of Japan Atherosclerosis Society, 1996
openaire   +2 more sources

CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. [PDF]

Nature
Rafei H, Basar R, Acharya S, Hsu YS, Liu P, Zhang D, Bohn T, Liang Q, Mohanty V, Upadhyay R, Li P, Phadatare P, Dede M, Xiong D, Fan H, Jones CM, Kunz S, Daher M, Nunez Cortes AK, Shanley M, Liu B, Moseley SM, Zhang C, Fang D, Banerjee P, Uprety N, Li Y, Shrestha R, Wan X, Shen H, Woods V, Gilbert AL, Rawal S, Dou J, Tan Y, Park JM, Reyes Silva F, Biederstädt A, Kaplan M, Jiang XR, Biederstädt I, Kumar B, Tiberti S, Moore M, Jin J, Yang RZ, Muniz-Feliciano L, Rosemore S, Lin P, Deyter GM, Fowlkes NW, Jain AK, Marin D, Maitra A, Chen K, Bopp T, Shpall EJ, Rezvani K.   +57 more
europepmc   +1 more source

IL-15 overexpression promotes memory program and anti-tumor activity of CD64 CAR T cells in a preclinical AML model. [PDF]

Commun Biol
Shan L, Li C, Li T, Wang C, Cui H, Pang A, Feng X.   +6 more
europepmc   +1 more source

Safety and efficacy of canine recombinant IL-15 in mammary gland tumors. [PDF]

Front Vet Sci
Kang MH, Lee J, Kim SK, Koh K, Kang MA, Park HM.   +5 more
europepmc   +1 more source

Novel fusion superkine, IL-24S/IL-15, enhances immunotherapy of brain cancer. [PDF]

J Immunother Cancer
Kumar A, Bhoopathi P, Mannangatti P, Maji S, Pradhan AK, Madan E, Klibanov AL, Gogna R, Limbrick DD, Emdad L, Das SK, Fisher PB.   +11 more
europepmc   +1 more source

IL-15 Superagonist SHR-1501 Enhances Immune Responses in Lung Cancer by Modulating Tumor Microenvironment. [PDF]

Clin Respir J
Zhang Q, Hu C, Jiang M, Wang Y, Luo H, Li X.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex

Journal of Clinical Immunology, 1996
IL-15 interacts with a heterotrimeric receptor that consists of the beta and gamma subunits of the IL-2 receptor (IL-2R) as well as a specific, high-affinity IL-15-binding subunit, which is designated IL-15R alpha. Since both the beta and the gamma subunits of the IL-2R are required for signaling by either IL-2 or IL-15, it is not surprising that these
M K, Kennedy, L S, Park
openaire   +2 more sources